PathAssist Derm is designed to analyze digital pathology images of skin lesions and aid pathologists in their review.
The Food and Drug Administration (FDA) has granted Breakthrough Device Designation to PathAI’s PathAssist Derm, an artificial intelligence-powered pathology solution designed to analyze digital pathology whole slide images of skin lesions and aid pathologists in their review.
The designation represents the latest regulatory achievement for PathAI, which recently received 510(k) clearance for AISight Dx, a digital pathology Image Management System cleared by the FDA with an authorized Predetermined Change Control Plan. The company also received European Medicines Agency and FDA qualification of AIM-MASH AI Assist as the first AI-powered pathology Drug Development Tool.
“This designation is a powerful acknowledgement of our AI capabilities and our commitment to bringing rigorously validated, clinically relevant tools to the field of digital pathology,” says Dr Andy Beck, chief executive officer at PathAI, in a release. “By working closely with the FDA through the Breakthrough Devices Program, we aim to accelerate the development and review process, ensuring that this technology reaches pathologists and patients as quickly as possible.”
Addressing Diagnostic Variability
PathAssist Derm aims to address critical challenges in dermatopathology, where substantial inter-observer variability exists, particularly in melanocytic lesions. A large study of pathologists found that both inter-observer concordance and accuracy compared to a consensus reference diagnosis were below 50% for diagnostically challenging lesion classes.
Skin cancer is the most commonly diagnosed cancer in the United States, placing increasing demand on pathology services. By leveraging advanced AI technology to support case assessment and workflow prioritization, PathAssist Derm is designed to help pathologists manage rising caseloads while maintaining diagnostic accuracy.
The Breakthrough Device Designation is intended to expedite the development and review of medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
PathAI will continue to partner with global regulators to advance AI-powered solutions that strengthen diagnostic confidence and improve patient care.
ID 287407594 © Katerynakon | Dreamstime.com
